Pediatric Brain Cancer:
U.S. Phase 1 Clinical Trial

 

Not Yet Recruiting

Pediatric Brain
Cancer:  U.S. Phase
1 Clinical Trial

 

Not Yet Recruiting

Pediatric
Brain
Cancer:
U.S. Phase
1 Clinical
Trial

 

Not Yet Recruiting

Trial Information

Pediatric brain cancer is relatively rare. However, cancer is the leading cause of death by disease among children in the U.S.  Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.

Plus Therapeutics is developing the Rhenium (186Re) Obisbemeda radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG).  The ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial is planned to start in 2025.

“Children with brain tumors have limited options & 186RNL delivered with a minimally invasive procedure could be an important new potential option for these patients.”

Michael G. DeCuypere, MD, PhD, FAANS

Northwestern University Feinberg School of Medicine

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

Ashley S. Plant, M.D.

Lurie Children’s Hospital of Chicago

SPECIALTIES:  CANCER & BLOOD DISORDERS

Ashley S. Plant, M.D. is an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and is an Assistant Professor of Pediatrics at Northwestern University. Dr. Plant received her medical degree from Stanford University School of Medicine. She completed her pediatrics residency at University of California, Los Angeles and her pediatric hematology/oncology fellowship at Dana Farber Cancer Institute/Boston Children’s Hospital. She completed additional training in neuro-oncology at Dana Farber Cancer Institute. Her research focus includes immunotherapy and the immune microenvironment as well as early phase clinical trial design for pediatric brain tumors.

Trial Locations

Please visit this website regularly for updates as new locations are added.

Lurie Children’s Hospital

Chicago, Illinois

What Can You Do Next?

Participating in a clinical trial is an important decision.  If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Request Information

2 + 11 =

News

 
April 9, 2024
 
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
 

November 29, 2023

Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

  • Presentation titled “Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors”

June 8, 2023

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

  • Plus Therapeutics announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.

August 21, 2021

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

June 10, 2021

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

Updates

Happy New Year 2025!

🎉 Happy New Year from Plus Therapeutics! 🎉 As we ring in the new year, we want to extend our heartfelt gratitude to the patients, medical staff, and the entire cancer community who have supported our mission throughout 2024. Thanks to your dedication and hard work,...

read more

Brains for the Cure

ReSPECT Clinical Trials on BrainsFortheCure.org What is Recurrent Glioblastoma (GBM)? Recurrent glioblastoma is a particularly aggressive form of brain cancer that tends to return after initial treatment. GBM recurrence is a major challenge for both patients and...

read more

NOW ONLINE: SNO 2024 Presentations

Missed Plus Therapeutics at SNO Annual 2024? Catch Our Latest Presentations Online – Including ReSPECT-LM Phase 1 Interim Data If you weren’t able to attend the SNO Annual Meeting 2024 this year, don’t worry – you can now access all our key presentations online! This...

read more

Happy Holidays 2024

🎄 Happy Holidays from Plus Therapeutics! 🎄 As the end of year year approaches, the Plus Therapeutics team wants to extend our warmest holiday greetings to all of our patients, partners, and supporters. We are taking some time this week to relax and recharge with our...

read more